Proteomic insights into non-small cell lung cancer: New ideas for cancer diagnosis and therapy from a functional viewpoint

EuPA Open Proteomics

Volumn 4, Issue , 2014, Pages 25-39

  Linxweiler, Johannes ^a   Kollipara, Laxmikanth ^b   Zahedi, René P ^b   Lampel, Pavel ^a   Zimmermann, Richard ^a   Greiner, Markus ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b LEIBNIZ INSTITUT FÜR ANALYTISCHE WISSENSCHAFTEN ISAS E V   (Germany)

Author keywords

2D DIGE; Epithelial mesenchymal transition (EMT); Non small cell lung cancer (NSCLC); Plastin 3; Sec62; Vimentin

Indexed keywords

PROTEOME; SMALL INTERFERING RNA;

ARTICLE; CALCIUM HOMEOSTASIS; CANCER DIAGNOSIS; CANCER THERAPY; CELL MIGRATION; CONTROLLED STUDY; DRUG RESISTANCE; GENE EXPRESSION; GENE FUNCTION; GENE OVEREXPRESSION; HEK293 CELL LINE; HUMAN; HUMAN TISSUE; MOLECULAR MECHANICS; NON SMALL CELL LUNG CANCER; ONCOGENE; PLASMID; PROTEIN DEPLETION; PROTEIN PROTEIN INTERACTION; PROTEOMICS; SEC62 GENE; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS;

EID: 84907276311     PISSN: None     EISSN: 22129685     Source Type: Journal    
DOI: 10.1016/j.euprot.2014.05.004     Document Type: Article

References (49)

1. Linxweiler M., Linxweiler J., Barth M., Benedix J., Jung V., Kim Y.J., et al. Sec62 bridges the gap from 3q amplification to molecular cell biology in non-small cell lung cancer. Am J Pathol 2012, 180:473-483.
2. Linxweiler M., Schorr S., Schäuble N., Jung M., Linxweiler J., Langer F., et al. Targeting cell migration and the endoplasmic reticulum stress response with calmodulin antagonists: a clinically tested small molecule phenocopy of SEC62 gene silencing in human tumor cells. BMC Cancer 2013, 13:574-587.
3. Greiner M., Kreutzer B., Jung V., Grobholz R., Hasenfus A., Stöhr R.F., et al. Silencing of the SEC62 gene inhibits migratory and invasive potential of various tumor cells. Int J Cancer/J Int Du Cancer 2011, 128:2284-2295.
4. Greiner M., Kreutzer B., Lang S., Jung V., Adolpho C., Unteregger G., et al. Sec62 protein content is crucial for the ER stress tolerance of prostate cancer. Prostate 2011, 71:1074-1083.
5. Hagerstrand D., Tong A., Schumacher S.E., Ilic N., Shen R.R., Cheung H.W., et al. Systematic interrogation of 3q26 identifies TLOC1 and SKIL as cancer drivers. Cancer Discov 2013, 3:1044-1057.
6. Muller L., Diaz de Escauriaza M., Lajoie P., Theis M., Jung M., Muller A., et al. Evolutionary gain of function for the ER membrane protein Sec62 from yeast to humans. Mol Biol Cell 2010, 21:691-703.
7. Lakkaraju A.K., Thankappan R., Mary C., Garrison J.L., Taunton J., Strub K. Efficient secretion of small proteins in mammalian cells relies on Sec62-dependent posttranslational translocation. Mol Biol Cell 2012, 23:2712-2722.
8. Lang S., Benedix J., Fedeles S.V., Schorr S., Schirra C., Schauble N., et al. Different effects of Sec61alpha, Sec62 and Sec63 depletion on transport of polypeptides into the endoplasmic reticulum of mammalian cells. J Cell Sci 2012, 125:1958-1969.
9. Ampofo E., Welker S., Jung M., Muller L., Greiner M., Zimmermann R., et al. CK2 phosphorylation of human Sec63 regulates its interaction with Sec62. Biochim Biophys Acta 2013, 1830:2938-2945.
10. Ishihama Y., Oda Y., Tabata T., Sato T., Nagasu T., Rappsilber J., et al. Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein. Mol Cell Proteom 2005, 4:1265-1272.
11. Wessel D., Flugge U.I. A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. Anal Biochem 1984, 138:141-143.
12. Balsara B.R., Testa J.R. Chromosomal imbalances in human lung cancer. Oncogene 2002, 21:6877-6883.
13. Björkqvist A.-M., Husgafvel-Pursiainen K., Anttila S., Karjalainen A., Tammilehto L., Mattson K., et al. DNA gains in 3q occur frequently in squamous cell carcinoma of the lung, but not in adenocarcinoma. Genes Chromosomes Cancer 1998, 22:79-82.
14. Tisdale M.J. Tumor-host interactions. J Cell Biochem 2004, 93:871-877.
15. Majczak G., Lilla S., Garay-Malpartida M., Markovic J., Medrano F.J., de Nucci G., et al. Prediction and biochemical characterization of intrinsic disorder in the structure of proteolysis-inducing factor/dermcidin. Genet Mol Res 2007, 6:1000-1011.
16. + exchanger NHE1 is intrinsically disordered: implications for NHE1 trafficking. Biochemistry 2011, 50:3469-3480.
17. Netea-Maier R.T., Hunsucker S.W., Hoevenaars B.M., Helmke S.M., Slootweg P.J., Hermus A.R., et al. Discovery and validation of protein abundance differences between follicular thyroid neoplasms. Cancer Res 2008, 68:1572-1580.
18. Brown L.M., Helmke S.M., Hunsucker S.W., Netea-Maier R.T., Chiang S.A., Heinz D.E., et al. Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue. Mol Carcinog 2006, 45:613-626.
19. Katanasaka Y., Ishii T., Asai T., Naitou H., Maeda N., Koizumi F., et al. Cancer antineovascular therapy with liposome drug delivery systems targeted to BiP/GRP78. Int J Cancer/J Int Du Cancer 2010, 127:2685-2698.
20. Vedrenne C., Klopfenstein D.R., Hauri H.P. Phosphorylation controls CLIMP-63-mediated anchoring of the endoplasmic reticulum to microtubules. Mol Biol Cell 2005, 16:1928-1937.
21. Wesierska-Gadek J., Gueorguieva M., Kramer M.P., Ranftler C., Sarg B., Lindner H. A new, unexpected action of olomoucine, a CDK inhibitor, on normal human cells: up-regulation of CLIMP-63, a cytoskeleton-linking membrane protein. J Cell Biochem 2007, 102:1405-1419.
22. Wesierska-Gadek J., Hajek S.B., Sarg B., Wandl S., Walzi E., Lindner H. Pleiotropic effects of selective CDK inhibitors on human normal and cancer cells. Biochem Pharmacol 2008, 76:1503-1514.
23. Rerole A.L., Jego G., Garrido C. Hsp70: anti-apoptotic and tumorigenic protein. Methods Mol Biol 2011, 787:205-230.
24. Garg M., Kanojia D., Seth A., Kumar R., Gupta A., Surolia A., et al. Heat-shock protein 70-2 (HSP70-2) expression in bladder urothelial carcinoma is associated with tumour progression and promotes migration and invasion. Eur J Cancer 2010, 46:207-215.
25. Gastpar R., Gehrmann M., Bausero M.A., Asea A., Gross C., Schroeder J.A., et al. Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells. Cancer Res 2005, 65:5238-5247.
26. Li Y., Zhang B., Wang X., Yan H., Chen G., Zhang X. Proteomic analysis of apoptosis induction in human lung cancer cells by recombinant MVL. Amino Acids 2011, 41:923-932.
27. Al-Saad S., Al-Shibli K., Donnem T., Persson M., Bremnes R.M., Busund L.T. The prognostic impact of NF-kappaB p105, Vimentin, E-cadherin and Par6 expression in epithelial and stromal compartment in non-small-cell lung cancer. Br J Cancer 2008, 99:1476-1483.
28. Satelli A., Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci 2011, 68:3033-3046.
29. Goldberg Y. Protein phosphatase 2A: who shall regulate the regulator?. Biochem Pharmacol 1999, 57:321-328.
30. Ruediger R., Ruiz J., Walter G. Human cancer-associated mutations in the Aalpha subunit of protein phosphatase 2A increase lung cancer incidence in Aalpha knock-in and knockout mice. Mol Cell Biol 2011, 31:3832-3844.
31. Ruckova E., Muller P., Nenutil R., Vojtesek B. Alterations of the Hsp70/Hsp90 chaperone and the HOP/CHIP co-chaperone system in cancer. Cell Mol Biol Lett 2012, 17:446-458.
32. Chao A., Lai C.H., Tsai C.L., Hsueh S., Hsueh C., Lin C.Y., et al. Tumor stress-induced phosphoprotein1 (STIP1) as a prognostic biomarker in ovarian cancer. PLoS ONE 2013, 8:e57084.
33. Rishi A.K., Zhang L., Boyanapalli M., Wali A., Mohammad R.M., Yu Y., et al. Identification and characterization of a cell cycle and apoptosis regulatory protein-1 as a novel mediator of apoptosis signaling by retinoid CD437. J Biol Chem 2003, 278:33422-33435.
34. Nakata T., Yokota T., Emi M., Minami S. Differential expression of multiple isoforms of the ELKS mRNAs involved in a papillary thyroid carcinoma. Genes, Chromosomes Cancer 2002, 35:30-37.
35. Castets F., Rakitina T., Gaillard S., Moqrich A., Mattei M.G., Monneron A. Zinedin, SG2NA, and striatin are calmodulin-binding, WD repeat proteins principally expressed in the brain. J Biol Chem 2000, 275:19970-19977.
36. Chen Y.K., Chen C.Y., Hu H.T., Hsueh Y.P. CTTNBP2, but not CTTNBP2NL, regulates dendritic spinogenesis and synaptic distribution of the striatin-PP2A complex. Mol Biol Cell 2012, 23:4383-4392.
37. Gordon J., Hwang J., Carrier K.J., Jones C.A., Kern Q.L., Moreno C.S., et al. Protein phosphatase 2a (PP2A) binds within the oligomerization domain of striatin and regulates the phosphorylation and activation of the mammalian Ste20-Like kinase Mst3. BMC Biochem 2011, 12:54.
38. Goudreault M., D'Ambrosio L.M., Kean M.J., Mullin M.J., Larsen B.G., Sanchez A., et al. A PP2A phosphatase high density interaction network identifies a novel striatin-interacting phosphatase and kinase complex linked to the cerebral cavernous malformation 3 (CCM3) protein. Mol Cell Proteom 2009, 8:157-171.
39. +)-binding protein, flanks the Wolf-Hirschhorn syndrome (WHS) critical region and is deleted in most WHS patients. Genomics 1999, 60:218-225.
40. Fraering P.C., Ye W., Strub J.M., Dolios G., LaVoie M.J., Ostaszewski B.L., et al. Purification and characterization of the human gamma-secretase complex. Biochemistry 2004, 43:9774-9789.
41. Gamble S.C., Chotai D., Odontiadis M., Dart D.A., Brooke G.N., Powell S.M., et al. Prohibitin, a protein downregulated by androgens, represses androgen receptor activity. Oncogene 2007, 26:1757-1768.
42. Dai Y., Ngo D., Jacob J., Forman L.W., Faller D.V. Prohibitin and the SWI/SNF ATPase subunit BRG1 are required for effective androgen antagonist-mediated transcriptional repression of androgen receptor-regulated genes. Carcinogenesis 2008, 29:1725-1733.
43. Bruneel A., Labas V., Mailloux A., Sharma S., Royer N., Vinh J., et al. Proteomics of human umbilical vein endothelial cells applied to etoposide-induced apoptosis. Proteomics 2005, 5:3876-3884.
44. Meyer H.A., Grau H., Kraft R., Kostka S., Prehn S., Kalies K.U., et al. Mammalian Sec61 is associated with Sec62 and Sec63. J Biol Chem 2000, 275:14550-14557.
45. Tyedmers J., Lerner M., Bies C., Dudek J., Skowronek M.H., Haas I.G., et al. Homologs of the yeast Sec complex subunits Sec62p and Sec63p are abundant proteins in dog pancreas microsomes. Proc Natl Acad Sci U S A 2000, 97:7214-7219.
46. Schulmann K., Brasch F.E., Kunstmann E., Engel C., Pagenstecher C., Vogelsang H., et al. HNPCC-associated small bowel cancer: clinical and molecular characteristics. Gastroenterology 2005, 128:590-599.
47. Mori Y., Sato F., Selaru F.M., Olaru A., Perry K., Kimos M.C., et al. Instabilotyping reveals unique mutational spectra in microsatellite-unstable gastric cancers. Cancer Res 2002, 62:3641-3645.
48. Klopfenstein D.R., Klumperman J., Lustig A., Kammerer R.A., Oorschot V., Hauri H.P. Subdomain-specific localization of CLIMP-63 (p63) in the endoplasmic reticulum is mediated by its luminal alpha-helical segment. J Cell Biol 2001, 153:1287-1300.
49. Nikonov A.V., Hauri H.P., Lauring B., Kreibich G. Climp-63-mediated binding of microtubules to the ER affects the lateral mobility of translocon complexes. J Cell Sci 2007, 120:2248-2258.